By vgreene, 22 June, 2015 Lifelong tx w/ nucleos(t)ide analogues<sup>5</sup> w/ high drug resistance barrier [S/L];<sup>6</sup> options:
By vgreene, 22 June, 2015 Entecavir:<sup>10</sup> 0.5 mg PO daily if compensated liver dz and lamivudine naïve; 1 mg PO daily if decompensated liver dz [S/M]
By vgreene, 22 June, 2015 Treat adults, adolescents, children w/ cirrhosis<sup>4</sup> regardless of ALT level, HBeAg status, or HBV DNA levels [S/M]
By vgreene, 22 June, 2015 Or, use noninvasive test (NIT) to determine liver dz stage at baseline [C/L]:
By vgreene, 22 June, 2015 Transient elastography (eg, FibroScan) or FibroTest:<sup>2</sup> may be preferred if available and cost not a concern
By vgreene, 22 June, 2015 APRI (AST-to-platelet ratio), score >2 consistent w/ cirrhosis:<sup>1</sup> preferred in resource-limited settings <a href=http://www.hepatitisc.uw.edu/page/clinical-calculators/apri><b>| View online APRI Calculator</b></a>
By vgreene, 22 June, 2015 Evaluate clinically for evidence of compensated or decompensated cirrhosis; features include:
By vgreene, 22 June, 2015 Other (hepatomegaly, splenomegaly, pruritus, fatigue, arthralgia, palmar erythema, edema)